Unlocking the brain to biologics
About us
Key2Brain is a Swedish biotechnology company committed to developing a novel and efficacious brain targeting platform technology.
With unique molecules and preclinical expertise, Key2Brain provides solutions for enhanced brain uptake of biologics and diagnostics. Key2Brain is a partner for preclinical development of therapeutics treating the central nervous system (CNS).
Our goal is to improve treatment and diagnostic options for diseases of the CNS.
The Team
Operations
Chao Su, PhD
Principal Scientist
Dominik Possner, PhD
Principal Scientist
Magnus Berglund, PhD
Chief Technical Officer
Elisabet Sjöström, PhD
Founder, CEO
Senior Consultant
Corporate Development and Strategy
Tiffany Dallas, MSc
Scientist
Scientific Advisory Board
Anna Sandegren, PhD
Tobias Cornvik, PhD
Stephen James, PhD
Stefan S Gelius, PhD
Board of Directors
Board Member, Andreas Gretander
Board Member, Stephen James
Board Member, Nina Fleck
Vice chair,
Kristina Magnusson Borg
Chair,
Elisabet O Sjöström
Photo: Rebecca Faresjö, Magnus Berglund
Contact
Email
info@key2brain.se
Visit us
Karolinska Institute Campus, Innomedicum, A Working Lab (AWL)
Nanna Svartz Väg 4, Solna
News
-
Key2Brain awarded VINNOVA funding
May 2023 -
Key2Brain was in May 2023 awarded “Innovative start-ups grant step 2” from VINNOVA, Sweden’s Innovation Agency
-
Team Expansion
June 2023 -
Key2Brain has expanded the team with core competence within Business Development and Science
-
Funding: VINNOVA Acceleration for deeptech companies
November 2023 -
Once again Key2Brain is supported by VINNOVA to accelerate our technology development
SEK 1 m funded for the first stage, with a possibility to get up to SEK 4 m in total over 3 years.